
Opinion|Videos|April 22, 2025
What Lies Ahead for GPP Diagnosis and Management
Panelists discuss how the future of generalized pustular psoriasis (GPP) diagnosis and management looks promising with emerging genetic testing for IL36RN mutations, development of multiple targeted biologics beyond IL-36 inhibitors, potential personalized treatment algorithms, improved disease classification, and enhanced multidisciplinary care approaches to better address this rare but severe dermatological condition.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
2
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
3
Introducing Dermatology Times NP/PA Connect
4
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
5









